Profile data is unavailable for this security.
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
- Revenue in USD (TTM)8.30m
- Net income in USD-46.96m
- Incorporated2014
- Employees53.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assembly Biosciences Inc | 28.33m | -40.80m | 104.31m | 65.00 | -- | 4.01 | -- | 3.68 | -7.54 | -7.54 | 5.14 | 4.09 | 0.373 | -- | -- | 435,784.60 | -53.73 | -39.69 | -79.14 | -44.03 | -- | -- | -144.05 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 104.80m | 127.00 | -- | 1.96 | -- | 20.96 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 105.13m | 9.00 | -- | 17.69 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| Annovis Bio Inc | 0.00 | -40.94m | 105.55m | 6.00 | -- | 14.39 | -- | -- | -3.76 | -3.76 | 0.00 | 0.5318 | 0.00 | -- | -- | 0.00 | -333.05 | -106.31 | -523.91 | -124.71 | -- | -- | -- | -- | -- | -3.51 | 0.00 | -- | -- | -- | -121.90 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 107.16m | 4.00 | -- | 4.92 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Immunic Inc | 0.00 | -96.90m | 110.80m | 77.00 | -- | 2.69 | -- | -- | -1.24 | -1.24 | 0.00 | 0.4576 | 0.00 | -- | -- | 0.00 | -147.12 | -72.09 | -213.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 111.75m | 93.00 | 7.74 | 1.18 | 6.19 | 198.49 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Cue Biopharma Inc | 8.30m | -46.96m | 112.59m | 53.00 | -- | 4.21 | -- | 13.57 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Bioatla Inc | 0.00 | -104.56m | 114.58m | 65.00 | -- | 3.65 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Karyopharm Therapeutics Inc | 148.44m | -87.48m | 114.93m | 325.00 | -- | -- | -- | 0.7743 | -0.7906 | -0.7906 | 1.17 | -1.27 | 0.6462 | 1.58 | 4.26 | 456,744.60 | -38.08 | -53.02 | -52.09 | -65.85 | 95.85 | 97.18 | -58.93 | -125.15 | 2.93 | -5.25 | 2.53 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 116.55m | 36.00 | 109.51 | -- | 42.62 | 2.38 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Invivyd Inc | 2.26m | -203.84m | 116.76m | 94.00 | -- | 0.8302 | -- | 51.57 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 117.73m | 233.00 | -- | -- | -- | 314.78 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 119.66m | 25.00 | -- | 3.87 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 120.30m | 102.00 | -- | 1.70 | -- | 1,010.90 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Cue Biopharma Inc's reporting currency: US Dollar USD
27.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bleichroeder LPas of 30 Sep 2024 | 5.00m | 10.27% |
| Slate Path Capital LPas of 30 Jun 2024 | 2.40m | 4.94% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.02m | 4.15% |
| Park City Capital LLCas of 05 Jun 2024 | 1.00m | 2.06% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 725.82k | 1.49% |
| Millennium Management LLCas of 30 Jun 2024 | 493.99k | 1.02% |
| Geode Capital Management LLCas of 30 Jun 2024 | 492.46k | 1.01% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 30 Jun 2024 | 478.50k | 0.98% |
| Sigma Planning Corp.as of 30 Sep 2024 | 401.33k | 0.83% |
| Good Life Advisors LLCas of 30 Sep 2024 | 400.00k | 0.82% |
More ▼
Data from 05 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
